Английская Википедия:Elinzanetant

Материал из Онлайн справочника
Версия от 01:20, 3 марта 2024; EducationBot (обсуждение | вклад) (Новая страница: «{{Английская Википедия/Панель перехода}} {{Short description|Chemical compound}} {{Drugbox | Verifiedfields = | Watchedfields = | verifiedrevid = | IUPAC_name = ''N''-[6-[(7''S'',9''aS'')-7-(hydroxymethyl)-3,4,6,7,9,9''a''-hexahydro-1''H''-pyrazino[2,1-c][1,4]oxazin-8-yl]-4-(4-fluoro-2-methylphenyl)pyridin-3-yl]-2-[3,5-bis(trifluoromethyl)phenyl]-''N'',2-dimethylpropanamide | image = Elinzanetant skeletal.svg | width = 250...»)
(разн.) ← Предыдущая версия | Текущая версия (разн.) | Следующая версия → (разн.)
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Elinzanetant (developmental code names BAY-3427080 GSK-1144814, NT-814) is an orally active small-molecule neurokinin/tachykinin NK1 receptor and NK3 receptor antagonist which is under development by Bayer, GlaxoSmithKline, and NeRRe Therapeutics for the treatment of hot flashes and "sex hormone disorders".[1][2] It has been found to relieve hot flashes in postmenopausal women and to dose-dependently suppress luteinizing hormone, estradiol, and progesterone levels in premenopausal women.[2][3] As of August 2021, elinzanetant is in phase 2 clinical trials for hot flashes and "sex hormone disorders".[1] It was also under development for the treatment of schizophrenia and opioid-related disorders, but development was discontinued for these uses.[1]

See also

References

Шаблон:Reflist

External links

Шаблон:Neurokinin receptor modulators

Шаблон:Nervous-system-drug-stub

Партнерские ресурсы
Криптовалюты
Магазины
Хостинг
Разное

  1. ↑ 1,0 1,1 1,2 Шаблон:Cite web
  2. ↑ 2,0 2,1 Шаблон:Cite journal
  3. ↑ Шаблон:Cite journal
Источник — http://wikihandbk.com/ruwiki/index.php?title=Английская_Википедия:Elinzanetant&oldid=14503256